The design and conduct of clinical trials to limit missing data

This article summarizes recommendations on the design and conduct of clinical trials of a National Research Council study on missing data in clinical trials. Key findings of the study are that (a) substantial missing data is a serious problem that undermines the scientific credibility of causal conclusions from clinical trials; (b) the assumption that analysis methods can compensate for substantial missing data is not justified; hence (c) clinical trial design, including the choice of key causal estimands, the target population, and the length of the study, should include limiting missing data as one of its goals; (d) missing-data procedures should be discussed explicitly in the clinical trial protocol; (e) clinical trial conduct should take steps to limit the extent of missing data; (f) there is no universal method for handling missing data in the analysis of clinical trials - methods should be justified on the plausibility of the underlying scientific assumptions; and (g) when alternative assumptions are plausible, sensitivity analysis should be conducted to assess robustness of findings to these alternatives. This article focuses on the panel's recommendations on the design and conduct of clinical trials to limit missing data. A companion paper addresses the panel's findings on analysis methods.

[1]  Yongman Kim Missing Data Handling in Chronic Pain Trials , 2011, Journal of biopharmaceutical statistics.

[2]  Richard E. White,et al.  Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations , 2010, PAIN®.

[3]  J H Shih,et al.  Sample size calculation for complex clinical trials with survival endpoints. , 1995, Controlled clinical trials.

[4]  Naihua Duan,et al.  Missing Data in Longitudinal Clinical Trials Part A: Design and Conceptual Issues. , 2008, Psychiatric annals.

[5]  C. Meinert Toward more definitive clinical trials. , 1980, Controlled clinical trials.

[6]  I. Piña,et al.  Clinical and analytical considerations in the study of health status in device trials for heart failure. , 2005, Journal of cardiac failure.

[7]  A. Breckenridge,et al.  Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial , 2010, The Lancet.

[8]  R. Little,et al.  The prevention and treatment of missing data in clinical trials. , 2012, The New England journal of medicine.

[9]  Laura Lyman Rodriguez,et al.  Committee on Assessing the System for Protecting Human Research Participants , 2002 .

[10]  D. Rubin INFERENCE AND MISSING DATA , 1975 .

[11]  E. Lakatos,et al.  Sample sizes based on the log-rank statistic in complex clinical trials. , 1988, Biometrics.

[12]  D. Hedeker,et al.  Bias reduction with an adjustment for participants' intent to dropout of a randomized controlled clinical trial , 2007, Clinical trials.

[13]  J Singh,et al.  European medicines evaluation agency , 2004 .

[14]  O H Frazier,et al.  Use of a continuous-flow device in patients awaiting heart transplantation. , 2007, The New England journal of medicine.

[15]  Zhang Jing,et al.  Guideline on missing data in confirmatory clinical trials , 2012 .

[16]  J. Bartlett Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV , 2004 .

[17]  Ezekiel J Emanuel,et al.  Undue Inducement: Nonsense on Stilts? , 2005, The American journal of bioethics : AJOB.